Table 2 Delivery characteristics
All deliveries (n = 322) | Deliveries followed by flare (n = 21) | Deliveries not followed by flare (n = 301) | p value | |
|---|---|---|---|---|
At delivery | ||||
Delivery | 0.431 | |||
First Second Third | 190 (59%) 109 (34%) 22 (7%) | 13 (62%) 8 (38%) 0 | 177 (59%) 101 (34%) 22 (7%) | |
Delivery mode | 0.002 | |||
Cesarean Vaginal | 153 (48%) 169 (52%) | 17 (81%) 4 (19%) | 136 (45%) 165 (55%) | |
Cesarean indication | 0.186 | |||
IBD-related Obstetrical Patient preference Other | 79/153 (51%) 71/153 (46%) 2/153 (1%) 1/153 (0.6%) | 13/17 (76%) 4/17 (23%) 0 0 | 66/136 (48%) 67/136 (49%) 2 (1%) 1 (1%) | |
Delivery complication | ||||
None Perianal laceration Episiotomy Conversion to C-section Instrumental | 250 (78%) 73 (23%) 0 0 1 (0.3%) | 18 (86%) 3 (14%) 0 0 0 | 232 (77%) 70 (23%) 0 0 1 (0.3%) | 0.358 |
Perianal status at delivery | < 0.001 | |||
Active Quiescent Healed None | 15 (5%) 20 (6%) 26 (8%) 261 (81%) | 9 (42%) 6 (29%) 2 (9%) 4 (19%) | 6 (2%) 14 (5%) 24 (8%) 257 (85%) | |
Meds before delivery | ||||
Steroids pre | 110 (34%) | 11 (52%) | 99 (32%) | 0.069 |
Biologics pre Adalimumab Certolizumab Infliximab Natalizumab | 113 (41%) 58 (18%) 16 (5%) 60 (19%) 0 | 15 (71%) 7 (33%) 1 (5%) 8 (38%) 0 | 118 (39%) 51 (17%) 15 (5%) 52 (17%) 0 | 0.004 0.059 0.964 0.018 |
Ustekinumab Vedolizumab | 9 (3%) 13 (4%) | 2 (9%) 2 (9%) | 7 (2%) 11 (4%) | 0.053 0.186 |
Immunomodulators pre 6-MP AZT Cyclosporine | 65 (20%) 28 (9%) 29 (9%) 0 | 7 (33%) 3 (14%) 4 (19%) 0 | 58 (19%) 25 98%) 25 (8%) 0 | 0.121 0.347 0.096 |
MTX | 8 (2%) | 0 | 8 (3%) | 0.449 |
Tofacitinib pre | 0 | |||
Other meds pre | ||||
5-ASA Antibiotic | 107 (33%) 5 (2%) | 5 (24%) 2 (10%) | 102 (34%) 3 (1%) | 0.343 0.002 |
Meds during delivery | ||||
Steroids during | 34 (11%) | 5 (24%) | 29 (10%) | 0.041 |
Biologics during Adalimumab Certolizumab Infliximab Natalizumab Ustekinumab Vedolizumab | 86 (27%) 38 (12%) 9 (3%) 23 (7%) 0 5 (2%) 11 (3%) | 13 (62%) 5 1 4 0 0 3 | 73 (24%) 33 8 19 0 5 8 | < 0.001 0.649 |
Immunomodulators during 6-MP AZT Cyclosporine MTX | 12 (4%) 7 (2%) 5 (2%) 0 0 | 2 (10%) 1 (5%) 1 (5%) 0 0 | 10 (3%) 6 (2%) 4 (1%) 0 0 | 0.147 |
Tofacitinib during | 1 (0.3%) | 1 (0.3%) | 0 | 0.791 |
Other meds during | ||||
5-ASA Antibiotic | 52 (16%) 7 (2%) | 3 (14%) 4 (19%) | 49 (16%) 3 (1%) | 0.810 < 0.001 |
Meds after delivery | ||||
Steroids post | 52 (16%) | 5 (24%) | 47 (16%) | 0.328 |
Biologics post Adalimumab Certolizumab Infliximab Natalizumab Ustekinumab Vedolizumab | 140 (43%) 56 (17%) 9 (3%) 39 (12%) 0 13 (4%) 23 (7%) | 17 (81%) 5 0 7 0 1 4 | 123 (41%) 51 9 32 0 12 19 | < 0.001 0.426 |
Immunomodulators post 6-MP AZT Cyclosporine | 33 (10%) 13 (4%) 17 (5%) 0 | 5 (24%) 2 (9%) 3 (14%) 0 | 28 (9%) 11 (4%) 14 (5%) 0 | 0.035 0.186 0.056 0.791 |
MTX | 1 (0.3%) | 0 | 1 (0.3%) | 0.791 |
Tofacitinib post | 0 | |||
Other meds post | ||||
5-ASA Ozanimod | 81 (25%) 1 (0.3%) | 4 (19%) 0 | 77 (26%) 1 (5%) | 0.505 < 0.001 |